Stefania Angelicola

IFN-γ and CD38 in Hyperprogressive Cancer Development

P. Lollini, A. Ardizzoni, P. Nanni, 2021, Cancers.

Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine

P. Lollini, J. Dorosz, Nicolaas A A Buijs, 2022, Biomedicines.

ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC

M. Ferracin, P. Lollini, M. Fiorentino, 2022, Translational lung cancer research.

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy

P. Lollini, P. Nanni, A. Palladini, 2023, International journal of molecular sciences.